DNA X, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DNA X, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $58.30M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $93.63M | Mar 31, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $50.92M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $93.63M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $69.83M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $54.57M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $63.99M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $116.25M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $135.67M | Mar 27, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.92M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $19.32M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.62M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.41M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $15.21M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $34.51M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $48.09M | Mar 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.66M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($33.65M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($90.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.09M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($38.63M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($29.93M) | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | ($25.83M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.28M | Mar 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.41M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.10M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $513.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.29M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($38.00M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($29.26M) | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | ($22.38M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $5.39M | Mar 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.24M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.77M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.97M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $17.70M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $16.22M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $26.06M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $23.25M | Mar 27, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.53M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($8.49M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($4.05M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.36M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($38.48M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($10.56M) | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | ($33.52M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $3.86M | Mar 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $214.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $36.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.0K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $46.0K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $11.0K | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $992.0K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $787.0K | Mar 27, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.90M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $39.74M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $56.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $53.69M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $41.09M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $50.31M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $55.46M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $67.35M | Mar 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.63M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $45.44M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $33.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $33.64M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $22.46M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $21.90M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $29.93M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $62.22M | Mar 27, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.96M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($5.70M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $22.37M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $20.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $18.63M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $28.41M | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | $25.53M | Jun 29, 2022 |
| FY2020 | Dec 31, 2018 | $5.13M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($89.91M) | Mar 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($304.27M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($283.61M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($249.96M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($249.87M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($234.81M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($196.18M) | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | ($166.25M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($143.53M) | Mar 27, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $5.34M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $9.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.21M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $11.23M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $22.14M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | $11.30M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $13.05M | Mar 27, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07M | Apr 15, 2026 |
| FY2020 | Dec 31, 2020 | $362.0K | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | $10.18M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $13.51M | Mar 27, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (28) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (128) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 20, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (28) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (128) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.27M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 276,881 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 4.43M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 40.77M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 18.81M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 6.63M | Jun 29, 2022 |
| FY2020 | Dec 31, 2019 | 20.44M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 15.59M | Mar 27, 2020 |